Laboratory Haemostasis Monitoring in COVID-19

Jecko Thachil, Ning Tang, Satoshi Gando, Anna Falanga, Marcel Levi, Cary Clark, Toshiaki Iba.

J Thromb Haemost. 2020, Online ahead of print.

DOACs and “Newer” Hemophilia Therapies in COVID-19: Reply

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T.

J  Thromb Haemost. 2020;18(7):1795-1796.

ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T

J Thromb Haemost. 2020;18(5):1023-1026.

Type and Dose of Heparin in Covid-19: Reply

Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T, Cattaneo M.

J Thromb Haemost. 2020. Online ahead of print.

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Bikdeli B, Madhavan BV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y,Tang LV,  Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP,  Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA,  Tafur AJ, Burton JR,  Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom GW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S,  Goldhaber SZ, Parikh SA, Monreal M,  Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH.

J Am Coll Cardiol. 2020 16;75(23):2950-2973.

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

6. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group. (2020).

Thromb Haemost. 2020;120(7):1004-1024

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A.

J Clin Oncol. 2020;38(5):496-520.

The Prevention and Management of Asparaginase-Related Venous Thromboembolism in Adults: Guidance From the SSC on Hemostasis and Malignancy of the ISTH

Zwicker JI, Wang TF, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, McMasters M, Carrier M

J Thromb Haemost. 2020;18(2):278-284.

Thrombotic Biomarkers for Risk Prediction of Malignant Disease Recurrence in Patients With Early Stage Breast Cancer

Giaccherini C, Marchetti M, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Tondini C, Barni S, Giuliani F, Petrelli F, D’Alessio A, Gasparini G, De Braud F, Santoro A, Labianca R, Falanga A

Haematologica, 2020; 105: 1704-1711

Thrombin generation predicts for early recurrence in breast cancer patients

Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Tondini C, Barni S, Giuliani F, Petrelli F, D’Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A; HYPERCAN Investigators.

J Thromb Haemost. 2020. Online ahead of print.

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey

11. Kakkar AK, Bauersachs R, Falanga A, Wong J, Kayani G, Kahney A, Hughes R, Levine M

Oncologist. 2020, Online ahead of print.

Clozapine-induced Anemia: A Case-Report

Eleftheriou G, Butera R, Barcella L, Falanga A.

Int J Clin Pharmacol Ther. 2020;58(5):289-292

Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study

Schieppati F, Russo L, Marchetti M, Barcella L, Cefis M, Gomez-Rosas P, Caldara G, Carpenedo M, D’Adda M, Rambaldi A, Savignano C, Billio A, Bruno Franco M, Toschi V, Falanga A (2020).

Am J Hematol. 2020, Online ahead of print.

Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment

Leader A, Ten Cate V, Ten Cate-Hoek AJ, Beckers EAM, Spectre G, Giaccherini C, Gurevich-Shapiro A, Krashin E, Raanani P, Schouten HC, Falanga A, Ten Cate H (2020).

Eur J Intern Med. 2020;77:86-96.

Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs

Poli D, Antonucci E, Vignini E, Martinese L, Testa S, Simioni P, Pengo V, Pignatelli P, Falanga A, Masciocco L, Barcellona D, Ciampa A, Chiarugi P, Paparo C, Ageno W, Palareti G, START2 Registry investigators (2020).

Eur J Intern Med. 2020, Online ahead of print.

D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study.

Gualtiero Palareti, Cristina Legnani, Emilia Antonucci, Benilde Cosmi, Daniela Poli, Sophie Testa, Alberto Tosetto, Walter Ageno, Anna Falanga, Piera Maria Ferrini, Vittorio Pengo, Paolo Prandoni, for the DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators.

Intern Emerg Med. 2020; 15(3): 453–462.

Treatment of venous thromboembolism in Northern Italy: A population-based study from 2013 to 2018.

Baviera M, Barcella L, Vannini T, Colacioppo P, Marzona I, Tettamanti M, Merlino L, Fortino I, Morra E, Falanga A, Roncaglioni MC.

Thromb Res. 2020 Epub 2020 Feb 20

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study

Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators.

J Clin Oncol. 2019;10;37(20):1713-1720

Treatment of venous thromboembolism with tinzaparin in oncological patients

Ageno W, Barni S, Di Nisio M, Falanga A, Imberti D, Labianca RF, Mantovani L.

Minerva Med. 2019;110(3):251-258.

Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment

Leader A, Ten Cate V, Ten Cate-Hoek AJ, Spectre G, Beckers EAM, Raanani P, Giaccherini C, Pereg D, Schouten HC, Falanga A, Ten Cate H.

Thromb Haemost. 2019;119(1):163-174.

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1).

Blood Transfus. 2018:1-10

Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction

Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P, Peterlongo P.

Front Oncol. 2018;8:480.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018;23(11):1372-1381.

Soluble stroma-related biomarkers of pancreatic cancer

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018;10(8). pii: e8741

Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins

Vignoli A, Marchetti M, Falanga A.

Ann Hematol. 2018 Sep;97(9):1555-1562.

Hemostatic biomarkers in cancer progression

Falanga A, Marchetti M.

Thromb Res. 2018 Apr;164 Suppl 1:S54-S61.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018;36(4):624-632.

Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016

Elalamy I, Falanga A.

Cancer Invest. 2018;36(1):73-91.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators.

N Engl J Med. 2018;378(7):615-624.

Mechanisms and risk factors of thrombosis in cancer

Falanga A, Russo L, Milesi V, Vignoli A.

Crit Rev Oncol Hematol. 2017;118:79-83.

Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism

D’Alessio A, Marchetti M, Tartari CJ, Russo L, Cecchini S, Lambregts KWFM, di Mauro D, Falanga A.

Cancer Invest. 2017;35(7):490-499.

Predicting APL lethal bleeding in the ATRA era

Falanga A.

Blood. 2017;129(13):1739-1740.

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party

Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V; GIMEMA Haemostasis and Thrombosis working party.

Blood Transfus. 2016 Nov;14(6):521-526.

Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors

Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, Mandalà M.

J Am Acad Dermatol. 2016;74(6):1254-1256.e4.

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality

Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA.

Oncologist. 2016;21(7):861-7.

Molecular biomarkers of thrombosis in myeloproliferative neoplasms

Barbui T, Falanga A.

Thromb Res. 2016;140 Suppl 1:S71-5.

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study

Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D’Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group.

Thromb Res. 2016;140 Suppl 1:S55-9.

Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer

Falanga A, Schieppati F, Russo D.

Semin Thromb Hemost. 2015;41(7):756-64.

The mechanisms of cancer-associated thrombosis

Falanga A, Marchetti M, Russo L.

Thromb Res. 2015;135 Suppl 1:S8-S11.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update

Lyman GH, Bohlke K, Falanga A; American Society of Clinical Oncology.

J Oncol Pract. 2015;11(3):e442-4.

Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: reply

Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M.

J Thromb Haemost. 2015;13(7):1352-3.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis

Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A.

J Thromb Haemost. 2015;13(6):1010-8.

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology.

J Clin Oncol. 2015;33(6):654-6.

Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH

Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M; Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis.

J Thromb Haemost. 2015;13(4):671-5.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall’Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P.

Hum Mol Genet. 2015;24(18):5345-55.

The coagulopathy of cancer

Falanga A, Russo L, Milesi V.

Curr Opin Hematol. 2014;21(5):423-9.

7th international conference on thrombosis and hemostasis issues in cancer. Preface

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2014;133 Suppl 2:ix.

Thrombosis in myeloproliferative neoplasms

Falanga A, Marchetti M.

Semin Thromb Hemost. 2014;40(3):348-58.

PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo

Catucci I, Peterlongo P, Ciceri S, Colombo M, Pasquini G, Barile M, Bonanni B, Verderio P, Pizzamiglio S, Foglia C, Falanga A, Marchetti M, Galastri L, Bianchi T, Corna C, Ravagnani F, Bernard L, Fortuzzi S, Sardella D, Scuvera G, Peissel B, Manoukian S, Tondini C, Radice P.

Genet Med. 2014;16(9):688-94.

Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia

Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B, Falanga A.

Am J Hematol. 2014;89(1):68-73.

Myeloproliferative neoplasms and thrombosis

Barbui T, Finazzi G, Falanga A.

Blood. 2013;122(13):2176-84

ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.

Panova-Noeva M, Marchetti M, Russo L, Tartari CJ, Leuzzi A, Finazzi G, Rambaldi A, ten Cate H, Falanga A.

Thromb Res. 2013;132(1):88-93.

Thrombosis and cancer: emerging data for the practicing oncologist

Lyman GH, Khorana AA, Falanga A.

Am Soc Clin Oncol Educ Book. 2013.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A; American Society of Clinical Oncology Clinical Practice.

J Clin Oncol. 2013;31(17):2189-204.

Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates

Vignoli A, Giaccherini C, Marchetti M, Verzeroli C, Gargantini C, Da Prada L, Giussani B, Falanga A.

Transfus Med Hemother. 2013;40(2):126-32.

Mechanisms of thrombosis in cancer

Falanga A, Russo L, Verzeroli C.

Thromb Res. 2013;131 Suppl 1:S59-62

Coagulation and cancer: biological and clinical aspects

Falanga A, Marchetti M, Vignoli A.

J Thromb Haemost. 2013;11(2):223-33.

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer

Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H.

J Thromb Haemost. 2013;11(1):71-80.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.

J Thromb Haemost. 2013 Jan;11(1):56-70.

Thrombotic disease in the myeloproliferative neoplasms

Falanga A, Marchetti M.

Hematology Am Soc Hematol Educ Program. 2012;2012:571-81

Venous thromboembolism in the hematologic malignancies

Falanga A, Marchetti M, Russo L.

Curr Opin Oncol. 2012 Nov;24(6):702-10

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival

Falanga A, Vignoli A, Diani E, Marchetti M.

Patient Relat Outcome Meas. 2011 Jul;2:175-88

6th International Conference on Thrombosis and Hemostasis Issues in Cancer. Preface

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2012 Apr;129 Suppl 1:ix.

Microparticles in tumor progression

Falanga A, Tartari CJ, Marchetti M.

Thromb Res. 2012 Apr;129 Suppl 1:S132-6.

Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography

Marchetti M, Diani E, ten Cate H, Falanga A.

Haematologica. 2012 Aug;97(8):1173-80.

Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies

Dienava-Verdoold I, Marchetti MR, te Boome LC, Russo L, Falanga A, Koene HR, Mertens K, Brinkman HJ.

Thromb Haemost. 2012 Mar;107(3):468-76.

Anticancer treatment and thrombosis

Falanga A, Marchetti M.

Thromb Res. 2012; 129(3):353-9.

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011;22 Suppl 6:vi85-92

Epidemiology, risk and outcomes of venous thromboembolism in cancer

Falanga A, Russo L.

Hamostaseologie. 2012;32(2):115-25.

Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visonà A; Italian Society for Haemostasis and Thrombosis.

Thromb Res. 2012;129(5):e171-6.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093.

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011;118(9):2599-601.

Defining the thrombotic risk in patients with myeloproliferative neoplasms.

Vianello F, Battisti A, Cella G, Marchetti M, Falanga A.

ScientificWorldJournal. 2011;11:1131-7.

All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.

Marchetti M, Russo L, Balducci D, Falanga A.

Thromb Res. 2011;128(4):368-74.

LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.

Vignoli A, Marchetti M, Russo L, Cantalino E, Diani E, Bonacina G, Falanga A.

Cancer Invest. 2011;29(2):153-61.

Treatment of thromboembolism in cancer patients.

Panova-Noeva M, Falanga A.

Expert Opin Pharmacother. 2010;11(12):2049-58

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010;21 Suppl 5:v274-6.

Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa, Italy, April 23-25, 2010. Preface.

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2010;125 Suppl 2:ix.

Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.

Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A.

Thromb Haemost. 2010;104(1):151-6.

Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.

Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santoro N, Marchetti M, De Mattia D, Falanga A.

Am J Hematol. 2010;85(5):325-30.

Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients.

Mandala M, Falanga A, Labianca R.

Ann Oncol. 2010;21(5):911-3.

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A.

Ann Oncol. 2010;21(4):871-6.

Venous thromboembolism in the hematologic malignancies.

Falanga A, Marchetti M.

J Clin Oncol. 2009;27(29):4848-57.

Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

Imberti D, Di Nisio M, Donati MB, Falanga A, Ghirarduzzi A, Guarneri D, Piovella F, Santoro RC, Baldini E, Zampogna S; Italian Society for Thrombosis and Haemostasis.

Thromb Res. 2009;124(5):e32-40.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.

J Clin Oncol. 2009;27(29):4919-26.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2009;20 Suppl 4:182-4

Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.

Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A.

Haematologica. 2009;94(7):911-8.

Thrombosis associated with angiogenesis inhibitors.

Elice F, Rodeghiero F, Falanga A, Rickles FR.

Best Pract Res Clin Haematol. 2009;22(1):115-28.

Procoagulant mechanisms in tumour cells.

Falanga A, Panova-Noeva M, Russo L.

Best Pract Res Clin Haematol. 2009;22(1):49-60.

The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.

Falanga A.

Cancer Invest. 2009;27(1):105-15.

Overview of the postulated mechanisms linking cancer and thrombosis.

ten Cate H, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):122-30.

Hemostatic complications of angiogenesis inhibitors in cancer patients.

Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F.

Am J Hematol. 2008;83(11):862-70.

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

Landolfi R, Di Gennaro L, Falanga A.

Leukemia. 2008;22(11):2020-8.

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A.

Blood. 2008;112(10):4061-8.

Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.

Falanga A, Barbui T, Rickles FR. Semin Thromb Hemost. 2008;34(2):204-10.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2008;19 Suppl 2:ii126-7.

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.

Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A.

Thromb Res. 2008;121(5):637-45.

Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.

Falanga A, Rickles FR.

Hematology Am Soc Hematol Educ Program. 2007:165-71.

Heparin in tumor progression and metastatic dissemination.

Falanga A, Marchetti M.

Semin Thromb Hemost. 2007;33(7):688-94.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 Sep;35(9):1476.

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.

J Clin Oncol. 2007;25(34):5490-505.

Anticoagulants and cancer survival.

Piccioli A, Falanga A, Prandoni P.

Semin Thromb Hemost. 2006;32(8):810-3.

Cancer and venous thromboembolism.

Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P.

Semin Thromb Hemost. 2006;32(7):694-9.

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

Mandalà M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S; working group AIOM.

Crit Rev Oncol Hematol. 2006;59(3):194-204.

Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.

Vignoli A., Marchetti M., Balducci D., Barbui T., Falanga A.

Haematologica. 2006;91(5):620.

The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma.

Mandalà M, Falanga A, Cremonesi M, Zaccanelli M, Floriani I, Viganò MG, Rosti A, Cazzaniga ME, Ferretti G, Cabiddu M, Barni S.

Thromb Haemost. 2006;95(4):752-4.